Investment
Features
FeesSafety
Academy
More
Pluang+

uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

Market News
29 Sep 2026
Andrew Wynn
View Source
Bearish
uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite mixed analyst views, the company plans to seek FDA approval based on the stronger three-year data. The therapy targets a rare brain disorder causing nerve cell breakdown, and the recent trial involved 12 high-dose patients. uniQure believes the four-year data may be understated due to missing information but remains focused on regulatory progress.

The uniQure (QURE) stock experienced a significant drop following mixed results on its AMT-130 gene therapy for Huntington's disease. For readers following the health sector, here is Pluang's market snapshot as of Sep 30, 2026 02:41 WIB: out of 100 priced US health stocks, 35 rose and 65 fell. Notable movers include AbCellera Biologics Inc (ABCL) with a price of USD 14.88 and a 1-day change of +6.90%, Heron Therapeutics Inc (HRTX) at USD 0.31 with +6.55%, and Summit Therapeutics Inc (SMMT) at USD 16.46 with +6.33%.

More News

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron projects record $51.33B revenue driven by AI memory demand, with EPS soaring to $31.72 this quarter.

Micron Technology is set to report record quarterly revenue of up to $51.33 billion, fueled by strong demand for high-bandwidth memory in the AI market. Earnings per share are expected to jump significantly to around $31.72, compared to $3.03 last ye...

Company Fundamentals
Bullish
16 minutes ago
Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma beats EPS estimates but misses revenue; acquisition deal boosts shares 35%.

Sangoma Technologies reported a smaller-than-expected loss with an EPS of -$0.08, beating analyst estimates of -$2.19, though its revenue of $48.55 million slightly missed expectations. Despite ongoing profitability challenges reflected in a negative...

Company Fundamentals
Bullish
2 hours ago
Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics raises 2026 revenue forecast with strong Q2 sales and analyst optimism.

Iovance Biotherapeutics has increased its full-year 2026 revenue guidance to $410-$420 million, reflecting nearly 60% growth driven by strong U.S. demand for its cancer therapy Amtagvi, which generated $91 million in Q2 sales. Analyst Joseph Pantgini...

Analyst Insights
Bullish
3 hours ago
First Financial Bank to open new full-service branch in Bee Cave, Texas, expanding in Austin area.

First Financial Bank to open new full-service branch in Bee Cave, Texas, expanding in Austin area.

First Financial Bank, a subsidiary of First Financial Bankshares, Inc., announced it will open a new full-service branch in Bee Cave, Texas, in late October. This marks the bank's 81st location and strengthens its presence in Central Texas and the gr...

Market News
Bullish
4 hours ago
Republic Services to report Q3 2026 earnings on Oct 29 with live investor call.

Republic Services to report Q3 2026 earnings on Oct 29 with live investor call.

Republic Services, a leading environmental services company, will announce its third quarter 2026 financial results after market close on October 29, 2026. The company will host a live investor conference call at 5 p.m. Eastern Time the same day, acc...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App